You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClopidogrel
Accession NumberDB00758  (APRD00444)
TypeSmall Molecule
GroupsApproved, Nutraceutical
DescriptionClopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
Structure
Thumb
Synonyms
(+)-Clopidogrel
Clopidogrelum
External Identifiers
  • SR-25990C
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-clopidogreltablet75 mgoralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Accel-clopidogreltablet75 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-clopidogreltablet300 mgoralAccel Pharma IncNot applicableNot applicableCanada
Act Clopidogreltablet75 mgoralActavis Pharma Company2011-12-07Not applicableCanada
Ag-clopidogreltablet75 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-clopidogreltablet75 mgoralAuro Pharma Inc2014-02-06Not applicableCanada
Bio-clopidogreltablet75 mgoralBiomed PharmaNot applicableNot applicableCanada
Clopidogreltablet75 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Clopidogreltablet75 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Clopidogreltablet75 mgoralSanis Health Inc2013-02-13Not applicableCanada
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet300 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet300 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet300 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet300 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Clopidogrel ZentivaFilm-coated tablet75 mgOral useSanofi Aventis2008-07-16Not applicableEu
Dom-clopidogreltablet75 mgoralDominion Pharmacal2012-09-26Not applicableCanada
Ipg-clopidogreltablet75 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-clopidogreltablet300 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-clopidogreltablet75 mgoralJamp Pharma Corporation2014-01-15Not applicableCanada
Mar-clopidogreltablet300 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-clopidogreltablet75 mgoralMarcan Pharmaceuticals Inc2015-01-21Not applicableCanada
Mint-clopidogreltablet75 mgoralMint Pharmaceuticals Inc2013-07-18Not applicableCanada
Mint-clopidogreltablet300 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-clopidogreltablet300 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-clopidogreltablet75 mgoralMylan Pharmaceuticals Ulc2011-12-07Not applicableCanada
Plavixtablet, film coated75 mg/1oralCardinal Health2007-09-20Not applicableUs
Plavixtablet, film coated75 mg/1oralSTAT Rx USA LLC1900-01-01Not applicableUs
Plavixtablet, film coated75 mg/1oralBristol Myers Squibb/Sanofi Pharmaceuticals Partnership1900-01-01Not applicableUs
Plavixtablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Plavixtablet, film coated300 mg/1oralCardinal Health1997-11-17Not applicableUs
Plavixtablet, film coated75 mg/1oralRebel Distributors Corp1900-01-01Not applicableUs
Plavixtablet300 mgoralSanofi Aventis Canada Inc2009-09-30Not applicableCanada
Plavixtablet, film coated300 mg/1oralBristol Myers Squibb/Sanofi Pharmaceuticals Partnership1900-01-01Not applicableUs
Plavixtablet, film coated75 mg/1oralA S Medication Solutions Llc1999-02-26Not applicableUs
Plavixtablet, film coated75 mg/1oralPd Rx Pharmaceuticals, Inc.1900-01-01Not applicableUs
Plavixtablet, film coated75 mg/1oralREMEDYREPACK INC.2013-03-192016-03-11Us
Plavixtablet, film coated75 mg/1oralContract Pharmacy Services Pa1999-02-26Not applicableUs
Plavixtablet, film coated75 mg/1oralPhysicians Total Care, Inc.2000-11-21Not applicableUs
Plavixtablet, film coated75 mg/1oralbryant ranch prepack1900-01-01Not applicableUs
Plavixtablet, film coated75 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Plavixtablet75 mgoralSanofi Aventis Canada Inc1998-10-13Not applicableCanada
PMS-clopidogreltablet75 mgoralPharmascience Inc2011-12-14Not applicableCanada
Priva-clopidogreltablet75 mgoralPharmapar IncNot applicableNot applicableCanada
Q-clopidogreltablet75 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-clopidogreltablet75 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-04-30Not applicableCanada
Rbx-clopidogreltablet75 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva Clopidogreltablet75 mgoralLaboratoire Riva Inc2012-07-24Not applicableCanada
Sandoz Clopidogreltablet75 mgoralSandoz Canada Incorporated2011-12-07Not applicableCanada
Teva-clopidogreltablet300 mgoralTeva Canada Limited2013-01-02Not applicableCanada
Teva-clopidogreltablet75 mgoralTeva Canada Limited2011-12-14Not applicableCanada
Torrent-clopidogreltablet75 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clopidogreltablet75 mgoralApotex Inc2011-12-19Not applicableCanada
Apo-clopidogreltablet300 mgoralApotex Inc2013-01-21Not applicableCanada
Clopidogreltablet, film coated300 mg/1oralAccord Healthcare Inc.2013-05-15Not applicableUs
Clopidogreltablet, film coated75 mg/1oralAmerican Health Packaging2012-06-142015-12-29Us
Clopidogreltablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Clopidogreltablet, film coated75 mg/1oralTeva Pharmaceuticals USA Inc2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralApotex Corp.2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralAmerican Health Packaging2014-03-14Not applicableUs
Clopidogreltablet, film coated300 mg/1oralCamber Pharmaceuticals, Inc.2015-06-18Not applicableUs
Clopidogreltablet, film coated300 mg/1oralWockhardt USA LLC.2012-11-13Not applicableUs
Clopidogreltablet, film coated75 mg/1oralCitron Pharma LLC2012-05-17Not applicableUs
Clopidogreltablet, film coated300 mg/1oralWockhardt Limited2012-11-13Not applicableUs
Clopidogreltablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Clopidogreltablet300 mg/1oralVensun Pharmaceuticals, Inc.2014-11-01Not applicableUs
Clopidogreltablet, film coated75 mg/1oralREMEDYREPACK INC.2014-12-18Not applicableUs
Clopidogreltablet, film coated75 mg/1oralLegacy Pharmaceutical Packaging2012-05-172016-01-31Us
Clopidogreltablet, film coated300 mg/1oralMajor Pharmaceuticals2015-04-06Not applicableUs
Clopidogreltablet, film coated75 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Clopidogreltablet, film coated75 mg/1oralAidarex Pharmaceuticals LLC2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralbryant ranch prepack2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralInternational Laboratories, Inc.2013-12-02Not applicableUs
Clopidogreltablet, film coated300 mg/1oralApotex Corp.2014-03-04Not applicableUs
Clopidogreltablet, film coated300 mg/1oralAmerican Health Packaging2014-03-28Not applicableUs
Clopidogreltablet75 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-09-30Not applicableUs
Clopidogreltablet, film coated75 mg/1oralClinical Solutions Wholesale2012-05-17Not applicableUs
Clopidogreltablet75 mg/1oralREMEDYREPACK INC.2015-05-23Not applicableUs
Clopidogreltablet, film coated75 mg/1oralCardinal Health2012-05-17Not applicableUs
Clopidogreltablet75 mg/1oralMacleods Pharmaceuticals Limited2012-10-16Not applicableUs
Clopidogreltablet, film coated75 mg/1oralReady Meds2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralApotex Corp.2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralAurobindo Pharma Limited2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralAccord Healthcare Inc.2013-05-15Not applicableUs
Clopidogreltablet, film coated75 mg/1oralDIRECT RX2014-01-01Not applicableUs
Clopidogreltablet, film coated300 mg/1oralAmerican Health Packaging2012-11-282015-12-29Us
Clopidogreltablet, film coated75 mg/1oralWockhardt Limited2012-05-22Not applicableUs
Clopidogreltablet75 mg/1oralVensun Pharmaceuticals, Inc.2014-11-01Not applicableUs
Clopidogreltablet, film coated75 mg/1oralWockhardt USA LLC.2012-05-22Not applicableUs
Clopidogreltablet, film coated75 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Clopidogreltablet, film coated75 mg/1oralLegacy Pharmaceutical Packaging2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralUnit Dose Services2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Clopidogreltablet, film coated75 mg/1oralMed Vantx, Inc.2012-05-17Not applicableUs
Clopidogreltablet, film coated75 mg/1oralCamber Pharmaceuticals, Inc.2015-06-18Not applicableUs
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel AcinoFilm-coated tablet75 mgOral useAcino Ag2009-07-28Not applicableEu
Clopidogrel Bisulfatetablet, film coated75 mg/1oralCardinal Health2012-06-08Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralREMEDYREPACK INC.2013-03-262016-04-05Us
Clopidogrel Bisulfatetablet, film coated75 mg/1oralBlenheim Pharmacal, Inc.2014-02-14Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralREMEDYREPACK INC.2013-02-182016-04-05Us
Clopidogrel Bisulfatetablet, film coated300 mg/1oralDr.Reddy's Laboratories Limited2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralMylan Institutional Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralCardinal Health2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated300 mg/1oralScie Gen Pharmaceuticals Inc2014-04-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralMylan Pharmaceuticals Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralPd Rx Pharmaceuticals, Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralProficient Rx LP2014-04-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated300 mg/1oralMylan Institutional Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralTorrent Pharmaceuticals Limited2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralPreferred Pharmaceuticals, Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralCardinal Health2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralREMEDYREPACK INC.2014-03-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralPhysicians Total Care, Inc.2012-05-25Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralScie Gen Pharmaceuticals Inc2014-04-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralCarilion Materials Management2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated300 mg/1oralGolden State Medical Supply, Inc.2014-09-15Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralSun Pharma Global FZE2012-05-18Not applicableUs
Clopidogrel Bisulfatetablet, film coated300 mg/1oralBlenheim Pharmacal, Inc.2016-03-01Not applicableUs
Clopidogrel Bisulfatetablet, film coated300 mg/1oralCardinal Health2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralREMEDYREPACK INC.2013-03-012016-04-05Us
Clopidogrel Bisulfatetablet, film coated300 mg/1oralMylan Pharmaceuticals Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralREMEDYREPACK INC.2014-06-03Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralDr.Reddy's Laboratories Limited2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralMajor Pharmaceuticals2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet, film coated75 mg/1oralGolden State Medical Supply, Inc.2012-05-17Not applicableUs
Clopidogrel Bisulfatetablet75 mg/1oralREMEDYREPACK INC.2013-02-20Not applicableUs
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Clopidogrel Ratiopharm GmbhFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-07-28Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopido Grel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel 1a PharmaFilm-coated tablet75 mgOral useAcino Pharma Gmb H  2009-07-28Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel Acino Pharma GmbhFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-09-21Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel HexalFilm-coated tablet75 mgOral useAcino Pharma Gmb H2009-07-28Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
Clopidogrel RatiopharmFilm-coated tablet75 mgOral useArchie Samuel S.R.O.2009-09-23Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clopidogrel Bisulfate
120202-66-6
Thumb
  • InChI Key: FDEODCTUSIWGLK-RSAXXLAASA-N
  • Monoisotopic Mass: 419.0264064
  • Average Mass: 419.9
DBSALT000029
Categories
UNIIA74586SNO7
CAS number113665-84-2
WeightAverage: 321.822
Monoisotopic: 321.059027158
Chemical FormulaC16H16ClNO2S
InChI KeyInChIKey=GKTWGGQPFAXNFI-HNNXBMFYSA-N
InChI
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate
SMILES
[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylacetate
  • Thienopyridine
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Methyl ester
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
PharmacodynamicsSince clopidogrel is a prodrug, it must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. This active metabolite selectively inhibits adenosine diphosphate (ADP) binding to its platelet P2Y12 receptor and subsequently the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Mechanism of actionThe active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. he drug specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel.
Related Articles
AbsorptionAbsorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food.
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic, extensive and rapid, by hydrolysis to the main circulating metabolite, a carboxylic acid derivative, which accounts for approximately 85% of the circulating drug-related compounds. A glucuronic acid derivative of the carboxylic acid derivative has also been found in plasma and urine. Neither the parent compound nor the carboxylic acid derivative has a platelet inhibiting effect.

SubstrateEnzymesProduct
Clopidogrel
2-OxoclopidogrelDetails
2-Oxoclopidogrel
Not Available
Active Metabolite of ClopidogrelDetails
Clopidogrel
Not Available
Clopidogrel carboxylic acid derivativeDetails
Route of eliminationFollowing an oral dose of 14C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing.
Half lifeCarboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.
ClearanceNot Available
ToxicityA single dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and rats, with 3000 mg/kg lethal to baboons. Symptoms included vomiting, breathing difficulty, hemorrhage, and prostration.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Clopidogrel Action PathwayDrug actionSMP00260
Clopidogrel Metabolism PathwayDrug metabolismSMP00610
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions17900275
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions17900275
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > APatients are poor metabolizers of clopidogrel. More likely to experience poor cardiovascular outcomes.8195181
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > APatients are poor metabolizers of clopidogrel. More likely to experience poor cardiovascular outcomes.19706858
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9847
Caco-2 permeable+0.5777
P-glycoprotein substrateSubstrate0.6664
P-glycoprotein inhibitor IInhibitor0.6556
P-glycoprotein inhibitor IIInhibitor0.5558
Renal organic cation transporterInhibitor0.6368
CYP450 2C9 substrateNon-substrate0.7407
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6339
CYP450 1A2 substrateInhibitor0.724
CYP450 2C9 inhibitorNon-inhibitor0.5223
CYP450 2D6 inhibitorInhibitor0.5712
CYP450 2C19 inhibitorInhibitor0.8071
CYP450 3A4 inhibitorNon-inhibitor0.7389
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9188
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.9911
Rat acute toxicity2.4887 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7548
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Dr reddys laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral300 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral75 mg/1
Film-coated tabletOral use75 mg
Tabletoral75 mg/1
Film-coated tabletOral use300 mg
Tabletoral300 mg
Tabletoral75 mg
Prices
Unit descriptionCostUnit
Plavix 300 mg tablet24.86USD tablet
Plavix 75 mg tablet9.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336777 No1995-08-222012-08-22Canada
CA2334870 No2005-03-152019-06-10Canada
US4847265 No1994-11-172011-11-17Us
US6429210 Yes1999-12-102019-12-10Us
US6504030 Yes1999-12-102019-12-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158 °CNot Available
water solubility50.78 mg/LNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0118 mg/mLALOGPS
logP3.84ALOGPS
logP4.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity84.93 m3·mol-1ChemAxon
Polarizability33.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (71.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Revital Lifshitz-Liron, “Novel crystal forms III, IV, V, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form I, compositions containing the new forms and methods of administering the new forms.” U.S. Patent US20030114479, issued June 19, 2003.

US20030114479
General References
  1. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20;352(3):238-44. [PubMed:15659723 ]
  2. Perry CG, Shuldiner AR: Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. [PubMed:23697979 ]
  3. Furlong MT, Savant I, Yuan M, Scott L, Mylott W, Mariannino T, Kadiyala P, Roongta V, Arnold ME: A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:36-41. doi: 10.1016/j.jchromb.2013.02.031. Epub 2013 Mar 1. [PubMed:23542721 ]
External Links
ATC CodesB01AC04
AHFS Codes
  • 20:12.18
PDB EntriesNot Available
FDA labelDownload (402 KB)
MSDSDownload (57.4 KB)
Interactions
Drug Interactions
Drug
AbciximabClopidogrel may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Clopidogrel can be increased when it is combined with Abiraterone.
AcenocoumarolClopidogrel may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Clopidogrel can be increased when it is combined with Acetaminophen.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clopidogrel.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clopidogrel.
AfatinibThe serum concentration of Clopidogrel can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Clopidogrel can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Clopidogrel can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Clopidogrel can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Clopidogrel can be increased when it is combined with Alfentanil.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clopidogrel.
AlprostadilAlprostadil may increase the anticoagulant activities of Clopidogrel.
AlprostadilClopidogrel may increase the antiplatelet activities of Alprostadil.
AlteplaseClopidogrel may increase the anticoagulant activities of Alteplase.
ALX-0081Clopidogrel may increase the anticoagulant activities of ALX-0081.
AmantadineThe serum concentration of Clopidogrel can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Clopidogrel can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clopidogrel.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clopidogrel.
AmiodaroneThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Clopidogrel.
AmitriptylineThe serum concentration of Clopidogrel can be increased when it is combined with Amitriptyline.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clopidogrel.
AmlodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel.
AmprenavirThe serum concentration of Clopidogrel can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clopidogrel.
AmrinoneThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amrinone.
AmsacrineThe serum concentration of Clopidogrel can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the anticoagulant activities of Clopidogrel.
AncrodClopidogrel may increase the anticoagulant activities of Ancrod.
AnistreplaseClopidogrel may increase the anticoagulant activities of Anistreplase.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clopidogrel.
Antithrombin III humanClopidogrel may increase the anticoagulant activities of Antithrombin III human.
ApixabanClopidogrel may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Clopidogrel can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Aprotinin.
ArdeparinClopidogrel may increase the anticoagulant activities of Ardeparin.
ArgatrobanClopidogrel may increase the anticoagulant activities of Argatroban.
ArmodafinilThe metabolism of Clopidogrel can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Artemether can be decreased when combined with Clopidogrel.
AstaxanthinClopidogrel may increase the anticoagulant activities of Astaxanthin.
AstemizoleThe serum concentration of Clopidogrel can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Clopidogrel can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Clopidogrel can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Clopidogrel can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Clopidogrel can be increased when it is combined with Atorvastatin.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Clopidogrel.
AzelastineAzelastine may increase the anticoagulant activities of Clopidogrel.
AzelastineClopidogrel may increase the antiplatelet activities of Azelastine.
AzelnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine.
AzimilideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azimilide.
AzithromycinThe serum concentration of Clopidogrel can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clopidogrel.
BarnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Barnidipine.
BatroxobinClopidogrel may increase the anticoagulant activities of Batroxobin.
BecaplerminClopidogrel may increase the anticoagulant activities of Becaplermin.
BemiparinClopidogrel may increase the anticoagulant activities of Bemiparin.
BenidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Benidipine.
BenzocaineThe serum concentration of Clopidogrel can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clopidogrel.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clopidogrel.
BepridilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.
BeraprostClopidogrel may increase the anticoagulant activities of Beraprost.
BexaroteneThe serum concentration of Clopidogrel can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Clopidogrel can be increased when it is combined with Biperiden.
BivalirudinClopidogrel may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Clopidogrel can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Clopidogrel can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Clopidogrel can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Clopidogrel can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Clopidogrel can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clopidogrel.
BuprenorphineThe serum concentration of Clopidogrel can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clopidogrel.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Clopidogrel.
BuspironeThe serum concentration of Clopidogrel can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Clopidogrel can be increased when it is combined with Cabazitaxel.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Clopidogrel.
CaffeineThe serum concentration of Clopidogrel can be increased when it is combined with Caffeine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Clopidogrel.
CanagliflozinThe serum concentration of Clopidogrel can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Clopidogrel can be increased when it is combined with Candesartan.
CangrelorClopidogrel may increase the anticoagulant activities of Cangrelor.
CapecitabineThe metabolism of Clopidogrel can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Clopidogrel can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Clopidogrel can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Clopidogrel.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clopidogrel.
CarvedilolThe serum concentration of Clopidogrel can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Clopidogrel can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Clopidogrel can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Clopidogrel.
CertoparinClopidogrel may increase the anticoagulant activities of Certoparin.
ChloramphenicolThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Chloramphenicol resulting in a loss in efficacy.
ChloroquineThe serum concentration of Clopidogrel can be increased when it is combined with Chloroquine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clopidogrel.
ChlorpromazineThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Clopidogrel can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Clopidogrel can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Clopidogrel can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Clopidogrel can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Clopidogrel can be increased when it is combined with Cilazapril.
CilnidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cilnidipine.
CilostazolClopidogrel may increase the anticoagulant activities of Cilostazol.
CimetidineThe serum concentration of Clopidogrel can be decreased when it is combined with Cimetidine.
CinnarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cinnarizine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clopidogrel.
CiprofloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Clopidogrel.
CitalopramThe serum concentration of Clopidogrel can be increased when it is combined with Citalopram.
Citric AcidClopidogrel may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Clopidogrel can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Clopidogrel can be decreased when combined with Clemastine.
ClevidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Clopidogrel.
ClofazimineThe serum concentration of Clopidogrel can be increased when it is combined with Clofazimine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clopidogrel.
ClomipramineThe serum concentration of Clopidogrel can be increased when it is combined with Clomipramine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Clopidogrel can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Clopidogrel.
CobicistatThe serum concentration of Clopidogrel can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Clopidogrel can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Clopidogrel can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Collagenase.
ConivaptanThe serum concentration of Clopidogrel can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Clopidogrel can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Clopidogrel can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.
CyclosporineThe metabolism of Clopidogrel can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Clopidogrel can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateClopidogrel may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Clopidogrel.
DaclatasvirThe serum concentration of Clopidogrel can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Clopidogrel can be increased when it is combined with Dactinomycin.
DalteparinClopidogrel may increase the anticoagulant activities of Dalteparin.
DanaparoidClopidogrel may increase the anticoagulant activities of Danaparoid.
DapsoneThe metabolism of Dapsone can be decreased when combined with Clopidogrel.
DarodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine.
DarunavirThe metabolism of Clopidogrel can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clopidogrel.
DasatinibDasatinib may increase the anticoagulant activities of Clopidogrel.
DaunorubicinThe serum concentration of Clopidogrel can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Clopidogrel can be decreased when it is combined with Deferasirox.
DefibrotideClopidogrel may increase the anticoagulant activities of Defibrotide.
DelavirdineThe metabolism of Clopidogrel can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Clopidogrel can be increased when it is combined with Desipramine.
DesirudinClopidogrel may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Clopidogrel can be increased when it is combined with Desloratadine.
DesmoteplaseClopidogrel may increase the anticoagulant activities of Desmoteplase.
DexamethasoneThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.
DextranClopidogrel may increase the anticoagulant activities of Dextran.
Dextran 40Clopidogrel may increase the anticoagulant activities of Dextran 40.
Dextran 70Clopidogrel may increase the anticoagulant activities of Dextran 70.
Dextran 75Clopidogrel may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Clopidogrel can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clopidogrel.
DiazepamThe metabolism of Diazepam can be decreased when combined with Clopidogrel.
DiclofenacThe serum concentration of Clopidogrel can be increased when it is combined with Diclofenac.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clopidogrel.
DicoumarolClopidogrel may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clopidogrel.
DigoxinThe serum concentration of Clopidogrel can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine.
DiltiazemThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Diltiazem.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Clopidogrel.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clopidogrel.
DipyridamoleClopidogrel may increase the anticoagulant activities of Dipyridamole.
DitazoleClopidogrel may increase the anticoagulant activities of Ditazole.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Clopidogrel.
DotarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Dotarizine.
DoxazosinThe serum concentration of Clopidogrel can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Clopidogrel can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Clopidogrel can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Clopidogrel can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Clopidogrel can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Clopidogrel can be decreased when combined with Dronedarone.
Drotrecogin alfaClopidogrel may increase the anticoagulant activities of Drotrecogin alfa.
Edetic AcidClopidogrel may increase the anticoagulant activities of Edetic Acid.
EdoxabanClopidogrel may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Clopidogrel can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Clopidogrel.
EfonidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine.
ElbasvirThe serum concentration of Clopidogrel can be increased when it is combined with Elbasvir.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Clopidogrel.
EnalaprilThe serum concentration of Clopidogrel can be increased when it is combined with Enalapril.
EnoxaparinClopidogrel may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Clopidogrel.
EperisoneThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Eperisone.
EpinastineEpinastine may increase the anticoagulant activities of Clopidogrel.
EpinastineThe metabolism of Epinastine can be decreased when combined with Clopidogrel.
EpoprostenolClopidogrel may increase the anticoagulant activities of Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Clopidogrel.
ErgonovineThe serum concentration of Clopidogrel can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Clopidogrel can be increased when it is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clopidogrel.
ErythromycinThe metabolism of Clopidogrel can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Clopidogrel can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleEsomeprazole may decrease the antiplatelet activities of Clopidogrel.
EstradiolThe metabolism of Estradiol can be decreased when combined with Clopidogrel.
EstramustineThe serum concentration of Clopidogrel can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Clopidogrel can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Clopidogrel can be decreased when it is combined with Estrone.
EstroneThe metabolism of Estrone can be decreased when combined with Clopidogrel.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clopidogrel.
Ethyl biscoumacetateClopidogrel may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clopidogrel.
EtoposideThe serum concentration of Clopidogrel can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Clopidogrel can be decreased when it is combined with Etravirine.
FelodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.
FendilineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline.
FentanylThe serum concentration of Clopidogrel can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Clopidogrel can be increased when it is combined with Fexofenadine.
FibrinolysinClopidogrel may increase the anticoagulant activities of Fibrinolysin.
FidaxomicinThe serum concentration of Clopidogrel can be increased when it is combined with Fidaxomicin.
FloxuridineThe metabolism of Clopidogrel can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Clopidogrel can be decreased when combined with Fluconazole.
FlunarizineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clopidogrel.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clopidogrel.
FluorouracilThe metabolism of Clopidogrel can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Clopidogrel can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Clopidogrel.
FlupentixolThe serum concentration of Clopidogrel can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Clopidogrel can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Clopidogrel can be increased when it is combined with Flurazepam.
FluvastatinThe metabolism of Clopidogrel can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel.
Fondaparinux sodiumClopidogrel may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe metabolism of Clopidogrel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clopidogrel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Clopidogrel can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Fusidic Acid.
GabapentinThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin.
GefitinibThe serum concentration of Clopidogrel can be increased when it is combined with Gefitinib.
GemfibrozilThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Gemfibrozil resulting in a loss in efficacy.
GenisteinThe serum concentration of Clopidogrel can be increased when it is combined with Genistein.
GlucosamineGlucosamine may increase the antiplatelet activities of Clopidogrel.
GlyburideThe serum concentration of Clopidogrel can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Clopidogrel can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Clopidogrel can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Grepafloxacin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clopidogrel.
HaloperidolThe serum concentration of Clopidogrel can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Clopidogrel.
HeparinClopidogrel may increase the anticoagulant activities of Heparin.
HirulogClopidogrel may increase the anticoagulant activities of Hirulog.
HydrocortisoneThe serum concentration of Clopidogrel can be increased when it is combined with Hydrocortisone.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel.
IbudilastIbudilast may increase the anticoagulant activities of Clopidogrel.
IbudilastClopidogrel may increase the antiplatelet activities of Ibudilast.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Clopidogrel.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Clopidogrel.
Icosapent ethylClopidogrel may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Clopidogrel can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Clopidogrel.
IfenprodilClopidogrel may increase the antiplatelet activities of Ifenprodil.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Clopidogrel.
IloprostClopidogrel may increase the anticoagulant activities of Iloprost.
ImatinibThe metabolism of Clopidogrel can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Clopidogrel can be increased when it is combined with Imipramine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Clopidogrel.
IndinavirThe serum concentration of Clopidogrel can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Clopidogrel can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Clopidogrel can be decreased when combined with Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Clopidogrel.
IsavuconazoniumThe metabolism of Clopidogrel can be decreased when combined with Isavuconazonium.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Clopidogrel.
IsoniazidThe metabolism of Clopidogrel can be decreased when combined with Isoniazid.
IsradipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Isradipine.
ItraconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Clopidogrel can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Clopidogrel can be increased when it is combined with Ivermectin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clopidogrel.
KetamineThe serum concentration of Clopidogrel can be increased when it is combined with Ketamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Clopidogrel.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clopidogrel.
KetoconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Ketoconazole.
LacidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine.
LamotrigineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine.
LansoprazoleThe serum concentration of Clopidogrel can be increased when it is combined with Lansoprazole.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Clopidogrel.
LapatinibThe serum concentration of Clopidogrel can be increased when it is combined with Lapatinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Clopidogrel.
LeflunomideThe metabolism of Clopidogrel can be decreased when combined with Leflunomide.
LepirudinClopidogrel may increase the anticoagulant activities of Lepirudin.
LercanidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine.
LevofloxacinThe serum concentration of Clopidogrel can be increased when it is combined with Levofloxacin.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.
LevothyroxineThe serum concentration of Clopidogrel can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Clopidogrel.
LidocaineThe serum concentration of Clopidogrel can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clopidogrel.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Clopidogrel.
LiothyronineThe serum concentration of Clopidogrel can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Clopidogrel can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Clopidogrel can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Clopidogrel can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Clopidogrel can be increased when it is combined with Loperamide.
LoperamideThe metabolism of Loperamide can be decreased when combined with Clopidogrel.
LopinavirThe serum concentration of Clopidogrel can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Clopidogrel can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Clopidogrel.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clopidogrel.
LosartanThe serum concentration of Clopidogrel can be increased when it is combined with Losartan.
LosartanThe metabolism of Losartan can be decreased when combined with Clopidogrel.
LovastatinThe metabolism of Clopidogrel can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Clopidogrel can be decreased when it is combined with Lumacaftor.
Magnesium SulfateThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be decreased when combined with Clopidogrel.
ManidipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Manidipine.
MaprotilineThe serum concentration of Clopidogrel can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Clopidogrel can be increased when it is combined with Mebendazole.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Clopidogrel.
MefloquineThe serum concentration of Clopidogrel can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Clopidogrel can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clopidogrel.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clopidogrel.
MeprobamateThe serum concentration of Clopidogrel can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clopidogrel.
MethadoneThe serum concentration of Clopidogrel can be increased when it is combined with Methadone.
MethadoneThe metabolism of Methadone can be decreased when combined with Clopidogrel.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clopidogrel.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Clopidogrel.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clopidogrel.
MetoprololThe serum concentration of Clopidogrel can be increased when it is combined with Metoprolol.
MexiletineThe metabolism of Clopidogrel can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Clopidogrel.
MibefradilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Mibefradil.
MiconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.
MidazolamThe metabolism of Midazolam can be decreased when combined with Clopidogrel.
MifepristoneThe metabolism of Clopidogrel can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Clopidogrel.
MilrinoneClopidogrel may increase the antiplatelet activities of Milrinone.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Clopidogrel.
MitomycinThe serum concentration of Clopidogrel can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Clopidogrel can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Clopidogrel can be decreased when it is combined with Mitoxantrone.
MoclobemideThe metabolism of Clopidogrel can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Clopidogrel can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Clopidogrel can be increased when it is combined with Morphine.
MorphineThe metabolism of Morphine can be decreased when combined with Clopidogrel.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Clopidogrel.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Clopidogrel.
NadroparinClopidogrel may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Clopidogrel can be decreased when it is combined with Nafcillin.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Clopidogrel.
NaltrexoneThe serum concentration of Clopidogrel can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Clopidogrel.
NaringeninThe serum concentration of Clopidogrel can be increased when it is combined with Naringenin.
NCX 4016Clopidogrel may increase the anticoagulant activities of NCX 4016.
NefazodoneThe serum concentration of Clopidogrel can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Clopidogrel can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Clopidogrel can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Clopidogrel can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Clopidogrel can be decreased when combined with Nevirapine.
NicardipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nicardipine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clopidogrel.
NicotineThe metabolism of Nicotine can be decreased when combined with Clopidogrel.
NifedipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine.
NiguldipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.
NilotinibThe metabolism of Clopidogrel can be decreased when combined with Nilotinib.
NiludipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niludipine.
NilvadipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine.
NimesulideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.
NimesulideClopidogrel may increase the antiplatelet activities of Nimesulide.
NimodipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine.
NisoldipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.
NitrazepamThe serum concentration of Clopidogrel can be increased when it is combined with Nitrazepam.
NitrendipineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.
NorethisteroneThe serum concentration of Clopidogrel can be decreased when it is combined with Norethisterone.
ObinutuzumabThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Obinutuzumab.
OlaparibThe metabolism of Clopidogrel can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Clopidogrel.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Clopidogrel.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Clopidogrel.
OmeprazoleOmeprazole may decrease the antiplatelet activities of Clopidogrel.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Clopidogrel.
OsimertinibThe serum concentration of Clopidogrel can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Clopidogrel.
OtamixabanClopidogrel may increase the anticoagulant activities of Otamixaban.
P-NitrophenolThe serum concentration of Clopidogrel can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Clopidogrel can be increased when it is combined with Paclitaxel.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Clopidogrel.
PalbociclibThe serum concentration of Clopidogrel can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Clopidogrel can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clopidogrel.
ParnaparinClopidogrel may increase the anticoagulant activities of Parnaparin.
ParoxetineThe serum concentration of Clopidogrel can be increased when it is combined with Paroxetine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Clopidogrel.
Peginterferon alfa-2bThe serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clopidogrel.
PentobarbitalThe metabolism of Clopidogrel can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel.
Pentosan PolysulfateClopidogrel may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Clopidogrel.
PerhexilineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Perhexiline.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clopidogrel.
PerindoprilThe serum concentration of Clopidogrel can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Clopidogrel.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clopidogrel.
PethidineThe metabolism of Pethidine can be decreased when combined with Clopidogrel.
PhenindioneClopidogrel may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Clopidogrel can be decreased when it is combined with Phenobarbital.
PhenprocoumonClopidogrel may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Clopidogrel can be increased when combined with Phenytoin.
PimozideThe serum concentration of Clopidogrel can be increased when it is combined with Pimozide.
PinaveriumThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pinaverium.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Clopidogrel.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Clopidogrel.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Clopidogrel.
PlasminClopidogrel may increase the anticoagulant activities of Plasmin.
Platelet Activating FactorThe serum concentration of Clopidogrel can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Clopidogrel can be increased when it is combined with Ponatinib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Clopidogrel.
PosaconazoleThe serum concentration of Clopidogrel can be increased when it is combined with Posaconazole.
PrasugrelClopidogrel may increase the anticoagulant activities of Prasugrel.
PravastatinThe serum concentration of Clopidogrel can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Clopidogrel can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Clopidogrel can be increased when it is combined with Prednisone.
PregabalinThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pregabalin.
PrenylamineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Prenylamine.
PrimidoneThe metabolism of Clopidogrel can be increased when combined with Primidone.
ProbenecidThe serum concentration of Clopidogrel can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Clopidogrel can be decreased when it is combined with Progesterone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clopidogrel.
PromethazineThe serum concentration of Clopidogrel can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Clopidogrel.
PropafenoneThe serum concentration of Clopidogrel can be increased when it is combined with Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Clopidogrel.
PropranololThe serum concentration of Clopidogrel can be increased when it is combined with Propranolol.
Protein CClopidogrel may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeClopidogrel may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Clopidogrel can be increased when it is combined with Protriptyline.
PyrimethamineThe metabolism of Clopidogrel can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Clopidogrel can be increased when it is combined with Quazepam.
QuercetinThe serum concentration of Clopidogrel can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Clopidogrel can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Clopidogrel can be increased when it is combined with Quinidine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Clopidogrel.
QuinineThe serum concentration of Clopidogrel can be increased when it is combined with Quinine.
QuinineThe metabolism of Quinine can be decreased when combined with Clopidogrel.
RabeprazoleThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy.
RanitidineThe serum concentration of Clopidogrel can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Clopidogrel can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Clopidogrel can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Clopidogrel can be increased when it is combined with Regorafenib.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Clopidogrel.
ReserpineThe serum concentration of Clopidogrel can be decreased when it is combined with Reserpine.
ResveratrolResveratrol may increase the anticoagulant activities of Clopidogrel.
ResveratrolClopidogrel may increase the antiplatelet activities of Resveratrol.
ReteplaseClopidogrel may increase the anticoagulant activities of Reteplase.
ReviparinClopidogrel may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Clopidogrel.
RidogrelClopidogrel may increase the antiplatelet activities of Ridogrel.
RifabutinThe metabolism of Clopidogrel can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Clopidogrel can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Clopidogrel.
RifapentineThe metabolism of Clopidogrel can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Clopidogrel can be increased when it is combined with Rilpivirine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Clopidogrel.
RisedronateThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate.
RitonavirThe serum concentration of Clopidogrel can be decreased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Clopidogrel.
RivaroxabanClopidogrel may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clopidogrel.
RolapitantThe serum concentration of Clopidogrel can be increased when it is combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Clopidogrel.
RopiniroleThe metabolism of Clopidogrel can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clopidogrel.
RosiglitazoneClopidogrel may increase the anticoagulant activities of Rosiglitazone.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Clopidogrel.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clopidogrel.
SaquinavirThe serum concentration of Clopidogrel can be decreased when it is combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Clopidogrel.
SCH-530348Clopidogrel may increase the antiplatelet activities of SCH-530348.
ScopolamineThe serum concentration of Clopidogrel can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Clopidogrel can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Clopidogrel can be increased when it is combined with Selegiline.
SelegilineThe metabolism of Selegiline can be decreased when combined with Clopidogrel.
SelexipagClopidogrel may increase the anticoagulant activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clopidogrel.
SertralineThe serum concentration of Clopidogrel can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Clopidogrel.
SevofluraneSevoflurane may increase the anticoagulant activities of Clopidogrel.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clopidogrel.
SildenafilThe metabolism of Clopidogrel can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Clopidogrel can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clopidogrel can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Clopidogrel can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clopidogrel.
SirolimusThe serum concentration of Clopidogrel can be decreased when it is combined with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Clopidogrel.
SorafenibThe serum concentration of Clopidogrel can be increased when it is combined with Sorafenib.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Clopidogrel.
SpironolactoneThe serum concentration of Clopidogrel can be increased when it is combined with Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Clopidogrel.
SRT501Clopidogrel may increase the antiplatelet activities of SRT501.
St. John's WortThe serum concentration of Clopidogrel can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Clopidogrel can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Clopidogrel can be increased when it is combined with Stiripentol.
StreptokinaseClopidogrel may increase the anticoagulant activities of Streptokinase.
StreptozocinThe serum concentration of Clopidogrel can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Clopidogrel can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Clopidogrel can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Clopidogrel can be increased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clopidogrel.
SulfisoxazoleThe metabolism of Clopidogrel can be decreased when combined with Sulfisoxazole.
SulodexideClopidogrel may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Clopidogrel can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Clopidogrel can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Clopidogrel can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Clopidogrel can be decreased when it is combined with Tacrolimus.
TAK-390MRThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with TAK-390MR resulting in a loss in efficacy.
TamoxifenThe serum concentration of Clopidogrel can be decreased when it is combined with Tamoxifen.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Clopidogrel.
Taurocholic AcidThe serum concentration of Clopidogrel can be increased when it is combined with Taurocholic Acid.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Clopidogrel.
TelaprevirThe metabolism of Clopidogrel can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Clopidogrel can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Clopidogrel can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Clopidogrel.
TemsirolimusThe serum concentration of Clopidogrel can be increased when it is combined with Temsirolimus.
TenecteplaseClopidogrel may increase the anticoagulant activities of Tenecteplase.
TenofovirThe metabolism of Clopidogrel can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Clopidogrel can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clopidogrel.
TerfenadineThe serum concentration of Clopidogrel can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide.
TesmilifeneTesmilifene may increase the anticoagulant activities of Clopidogrel.
TesmilifeneClopidogrel may increase the antiplatelet activities of Tesmilifene.
TestosteroneThe serum concentration of Clopidogrel can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clopidogrel.
TheophyllineThe metabolism of Clopidogrel can be decreased when combined with Theophylline.
ThiotepaThe metabolism of Clopidogrel can be decreased when combined with Thiotepa.
TicagrelorClopidogrel may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe serum concentration of Clopidogrel can be increased when it is combined with Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Clopidogrel.
TinzaparinClopidogrel may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Clopidogrel.
TirofibanClopidogrel may increase the anticoagulant activities of Tirofiban.
TocilizumabThe serum concentration of Clopidogrel can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Clopidogrel can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tolfenamic Acid.
TolvaptanThe serum concentration of Clopidogrel can be increased when it is combined with Tolvaptan.
TopiramateThe metabolism of Clopidogrel can be decreased when combined with Topiramate.
TorasemideThe metabolism of Torasemide can be decreased when combined with Clopidogrel.
TositumomabThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.
TramadolThe metabolism of Tramadol can be decreased when combined with Clopidogrel.
TranilastThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.
TranilastClopidogrel may increase the antiplatelet activities of Tranilast.
TranylcypromineThe metabolism of Clopidogrel can be decreased when combined with Tranylcypromine.
TrapidilTrapidil may increase the anticoagulant activities of Clopidogrel.
TrapidilClopidogrel may increase the antiplatelet activities of Trapidil.
TrazodoneThe serum concentration of Clopidogrel can be decreased when it is combined with Trazodone.
TreprostinilClopidogrel may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Clopidogrel.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clopidogrel.
TrifluoperazineThe serum concentration of Clopidogrel can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Clopidogrel can be increased when it is combined with Triflupromazine.
TriflusalClopidogrel may increase the anticoagulant activities of Triflusal.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clopidogrel.
TrimethoprimThe serum concentration of Clopidogrel can be decreased when it is combined with Trimethoprim.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clopidogrel.
TrimipramineThe serum concentration of Clopidogrel can be increased when it is combined with Trimipramine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clopidogrel.
TroleandomycinThe serum concentration of Clopidogrel can be increased when it is combined with Troleandomycin.
UrokinaseClopidogrel may increase the anticoagulant activities of Urokinase.
Valproic AcidThe metabolism of Clopidogrel can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Clopidogrel can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Clopidogrel can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Clopidogrel can be decreased when combined with Venlafaxine.
VerapamilThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.
VerapamilThe metabolism of Verapamil can be decreased when combined with Clopidogrel.
VinblastineThe serum concentration of Clopidogrel can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Clopidogrel can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Clopidogrel can be increased when it is combined with Vinorelbine.
Vitamin EVitamin E may increase the antiplatelet activities of Clopidogrel.
VorapaxarClopidogrel may increase the anticoagulant activities of Vorapaxar.
VoriconazoleThe metabolism of Clopidogrel can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clopidogrel.
WarfarinClopidogrel may increase the anticoagulant activities of Warfarin.
XimelagatranClopidogrel may increase the anticoagulant activities of Ximelagatran.
XylometazolineThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline.
ZafirlukastThe metabolism of Clopidogrel can be decreased when combined with Zafirlukast.
ZiconotideThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Clopidogrel.
ZimelidineThe serum concentration of Clopidogrel can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Clopidogrel can be decreased when combined with Ziprasidone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Clopidogrel.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da
References
  1. Dorsam RT, Murugappan S, Ding Z, Kunapuli SP: Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003 Dec;8(6):359-65. [PubMed:14668029 ]
  2. Herbert JM, Savi P: P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. [PubMed:15199474 ]
  3. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 Aug;92(2):311-6. [PubMed:15269827 ]
  4. Wang L, Jacobsen SE, Bengtsson A, Erlinge D: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004 Aug 3;5:16. [PubMed:15291969 ]
  5. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1810-5. Epub 2004 Aug 12. [PubMed:15308557 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008. [PubMed:19463375 ]
  8. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11069-74. Epub 2006 Jul 11. [PubMed:16835302 ]
  9. van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):518-23. Epub 2003 Jan 23. [PubMed:12615691 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003 Aug 26;108(8):921-4. Epub 2003 Aug 18. [PubMed:12925453 ]
  3. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. Eur Heart J. 2003 Oct;24(19):1744-9. [PubMed:14522569 ]
  4. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 Jan 20;109(2):166-71. Epub 2004 Jan 5. [PubMed:14707025 ]
  5. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA: Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005 Jan;91(1):23-6. [PubMed:15604326 ]
  6. Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P: Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005 Feb;96(2):103-10. [PubMed:15679472 ]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  8. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 Jan;31(1):53-9. [PubMed:12485953 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS: Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013 Mar;344(3):665-72. doi: 10.1124/jpet.112.201640. Epub 2012 Dec 28. [PubMed:23275066 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E: Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501. [PubMed:17112805 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28